The controversial side of weight loss drugs: Unveiling the hidden ingredient in Ozempic and Wegovy tablets
Are the benefits of popular weight loss medications worth the potential risks? Researchers at Adelaide University are shedding light on a hidden ingredient in Ozempic and Wegovy tablets that may have unforeseen consequences for gut health. Their study reveals that salcaprozate sodium (SNAC), a compound designed to enhance drug absorption, could be doing more than just its intended job.
This groundbreaking research is the first of its kind to investigate the effects of repeated exposure to SNAC on gut microbiota, metabolic function, and health markers in animals. Over a 21-day period, scientists made several intriguing observations:
- A decline in beneficial gut bacteria that break down dietary fiber, potentially impacting digestion and nutrient absorption.
- Lower levels of short-chain fatty acids, which are crucial for gut lining health and inflammation control.
- Increased inflammatory markers in the blood, suggesting a potential link to systemic inflammation.
- Greater liver weight, which may indicate low-grade inflammation.
- A smaller cecum, the part of the intestine where gut bacteria break down fiber and produce protective compounds.
- Reduced levels of a brain-derived protein associated with cognitive impairment.
While the study doesn't prove harm, it does raise questions about the long-term effects of SNAC. As more people opt for oral versions of these medications, understanding the impact of repeated, long-term exposure to all ingredients becomes crucial.
Why SNAC is used in Semaglutide Tablets
Semaglutide, the active ingredient in Ozempic and Wegovy, is administered via injection or tablet. In tablet form, SNAC plays a vital role in shielding the drug from stomach enzymes and facilitating its entry into the bloodstream. Without SNAC, oral semaglutide would be ineffective.
The US approved a tablet version of Wegovy late last year, and with pills being seen as more convenient and potentially cost-effective, the use of SNAC in these medications is likely to increase. This raises concerns about the potential health implications of daily exposure to SNAC.
The Rising Use of Obesity Medications
Obesity remains a significant global health concern, affecting around 890 million adults and 160 million children worldwide. The US has the highest rate among OECD countries, with 43% of people aged 15 and older affected, followed by Australia at 31%.
Prescriptions for medications like Ozempic and Wegovy have surged in Australia in recent years, mirroring global trends. As these medications become more widely used, understanding their long-term effects is essential.
Researchers Call for Further Investigation
Amin Ariaee, a PhD candidate at Adelaide University and lead author of the study, emphasizes the importance of fully understanding the impact of all ingredients in these medications over time.
"Obesity is a complex, chronic disease with serious health consequences. These medicines are highly effective and are helping many people," Ariaee says. "But as oral versions become more widely used, we need to understand what repeated, long-term exposure to all ingredients in the pill means for the body -- not just the active drug."
While SNAC enables the effectiveness of semaglutide in tablet form, the study found associations with potentially harmful gut bacteria, elevated inflammatory markers, and depletion of proteins linked to cognitive impairment. These findings warrant further investigation, and researchers caution that more research is needed to fully understand the implications.
Senior Research Fellow Dr. Paul Joyce highlights the need for caution when interpreting the findings, as they are based on animal research. "Importantly, our findings do not prove that SNAC causes harm in humans," Dr. Joyce says. "However, they do show that the ingredient enabling these tablets to work may have adverse biological effects beyond drug absorption."
As the use of obesity medications expands globally, evaluating all components of these therapies, not just the active compound, becomes increasingly important. This study serves as a reminder that even seemingly innocuous ingredients can have unforeseen consequences, and further research is needed to ensure the safety and efficacy of these medications.
